BioMarin Pharmaceutical (NASDAQ:BMRN – Get Rating) was upgraded by equities research analysts at StockNews.com from a "hold" rating to a "buy" rating in a research report issued to clients and investors on Tuesday.

A number of other brokerages have also issued reports on BMRN. Jefferies Financial Group reissued a "buy" rating and issued a $100.00 price target on shares of BioMarin Pharmaceutical in a report on Wednesday, May 4th. Robert W. Baird reaffirmed an "outperform" rating and set a $112.00 target price on shares of BioMarin Pharmaceutical in a research note on Tuesday, June 28th. Wedbush reaffirmed a "hold" rating and set a $70.00 target price on shares of BioMarin Pharmaceutical in a research note on Friday, June 24th. Stifel Nicolaus reaffirmed a "buy" rating and set a $96.00 target price on shares of BioMarin Pharmaceutical in a research note on Tuesday, May 3rd. Finally, SVB Leerink lifted their target price on shares of BioMarin Pharmaceutical from $115.00 to $122.00 and gave the company an "outperform" rating in a research note on Thursday, August 4th. Three investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat.com, BioMarin Pharmaceutical currently has a consensus rating of "Moderate Buy" and an average target price of $110.93.

BioMarin Pharmaceutical Price Performance

Shares of BioMarin Pharmaceutical stock opened at $96.00 on Tuesday. The firm has a market cap of $17.81 billion, a PE ratio of 369.24, a price-to-earnings-growth ratio of 1.97 and a beta of 0.33. BioMarin Pharmaceutical has a 12-month low of $70.73 and a 12-month high of $97.76. The company has a quick ratio of 3.69, a current ratio of 5.42 and a debt-to-equity ratio of 0.24. The company's fifty day simple moving average is $83.95 and its two-hundred day simple moving average is $82.44.

Insiders Place Their Bets

In other BioMarin Pharmaceutical news, EVP Jeffrey Robert Ajer sold 1,308 shares of BioMarin Pharmaceutical stock in a transaction dated Thursday, May 26th. The shares were sold at an average price of $78.94, for a total value of $103,253.52. Following the completion of the transaction, the executive vice president now directly owns 54,109 shares of the company's stock, valued at $4,271,364.46. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other BioMarin Pharmaceutical news, CFO Brian Mueller sold 7,337 shares of BioMarin Pharmaceutical stock in a transaction dated Friday, July 8th. The shares were sold at an average price of $89.50, for a total value of $656,661.50. Following the completion of the transaction, the chief financial officer now directly owns 30,726 shares of the company's stock, valued at $2,749,977. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Jeffrey Robert Ajer sold 1,308 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Thursday, May 26th. The stock was sold at an average price of $78.94, for a total transaction of $103,253.52. Following the completion of the sale, the executive vice president now owns 54,109 shares of the company's stock, valued at $4,271,364.46. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 22,248 shares of company stock valued at $2,024,890. Insiders own 1.75% of the company's stock.

Institutional Trading of BioMarin Pharmaceutical

A number of large investors have recently made changes to their positions in the stock. Synovus Financial Corp grew its stake in shares of BioMarin Pharmaceutical by 2.5% in the second quarter. Synovus Financial Corp now owns 20,067 shares of the biotechnology company's stock worth $1,657,000 after acquiring an additional 485 shares during the period. Sivik Global Healthcare LLC grew its stake in shares of BioMarin Pharmaceutical by 18.8% in the second quarter. Sivik Global Healthcare LLC now owns 47,500 shares of the biotechnology company's stock worth $3,936,000 after acquiring an additional 7,500 shares during the period. Principal Financial Group Inc. grew its stake in shares of BioMarin Pharmaceutical by 2.8% in the second quarter. Principal Financial Group Inc. now owns 44,475 shares of the biotechnology company's stock worth $3,685,000 after acquiring an additional 1,193 shares during the period. Desjardins Global Asset Management Inc. grew its stake in shares of BioMarin Pharmaceutical by 43.2% in the second quarter. Desjardins Global Asset Management Inc. now owns 815 shares of the biotechnology company's stock worth $67,000 after acquiring an additional 246 shares during the period. Finally, Cerity Partners LLC bought a new stake in shares of BioMarin Pharmaceutical in the second quarter worth approximately $273,000. 95.45% of the stock is currently owned by institutional investors.

BioMarin Pharmaceutical Company Profile

(Get Rating)

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

See Also

• Get a free copy of the StockNews.com research report on BioMarin Pharmaceutical (BMRN)
• The 2 Dow Stocks with Decade-Long Win Streaks on the Line
• Could Rite Aid Be an Acquisition Target, Again?
• The How And Why of Investing in Oil Stocks
• The How and Why of Investing in Gold Stocks
• Workhorse Group Is Ready To Get Back On The Horse

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.